Sickle cell disease (a hemoglobinopathy—see Sidebar 1: Anemias Caused by Hemolysis: Hemoglobinopathies) causes a chronic hemolytic anemia occurring almost exclusively in blacks, caused by homozygous inheritance of Hb S. Sickle-shaped RBCs clog capillaries, causing organ ischemia. Acute exacerbations (crises) may develop frequently. Infection, bone marrow aplasia, or lung involvement (acute chest syndrome) can develop acutely and be fatal. Normocytic hemolytic anemia is characteristic. Diagnosis requires Hb electrophoresis. Crises are treated with analgesics and other supportive measures. Transfusions are occasionally required. Vaccines against bacterial infections, prophylactic antibiotics, and aggressive treatment of infections prolong survival. Hydroxyurea may decrease the frequency of crises.
Homozygotes (about 0.3% of blacks in the US) have sickle cell anemia; heterozygotes (8 to 13% of blacks) are typically not anemic.
In Hb S, valine is substituted for glutamic acid in the 6th amino acid of the β chain. Oxygenated Hb S is much less soluble than oxygenated Hb A; it forms a semisolid gel that causes RBCs to deform in a sickle shape at sites of low PO2. Distorted, inflexible RBCs adhere to vascular endothelium and plug small arterioles and capillaries, which leads to infarction. Venous plugging predisposes to thromboses. Because sickled RBCs are fragile, the mechanical trauma of circulation causes hemolysis. Chronic compensatory marrow hyperactivity deforms the bones.
Acute exacerbations (crises) occur intermittently, often for no known reason. In some cases, fever, viral infection, or local trauma appears to precipitate a crisis.
Painful crisis is the most common type; it is caused by ischemia and infarction, typically of the bones, but also of the spleen, lung, or kidney.
Aplastic crisis occurs when marrow erythropoiesis slows during acute infection (especially viral), during which an acute erythroblastopenia may occur.
Acute chest syndrome results from pulmonary microvascular occlusion and is a common cause of death, with mortality rates of up to 10%. It occurs in all age groups but is most common in childhood. Repeated episodes predispose to chronic pulmonary hypertension.
In children, acute sequestration of sickled cells in the spleen may occur, exacerbating anemia.
Priapism, a serious complication that can cause erectile dysfunction, is most common in young men.
Long-term consequences include impaired growth and development. Increased susceptibility to infection, particularly pneumococcal and Salmonella infections (including Salmonella osteomyelitis), also results. These infections are especially common in early childhood and can be rapidly fatal.
Other consequences include ischemic stroke, CNS vasculitis, avascular necrosis of the hips, renal concentrating defects, renal failure, heart failure, and pulmonary fibrosis.
Symptoms and Signs
Most symptoms occur only in patients who are homozygous and result from anemia and vaso-occlusive events resulting in tissue ischemia and infarction. Anemia is usually severe but varies highly among patients; mild jaundice and pallor are common.
Patients may be poorly developed and often have a relatively short trunk with long extremities and a tower-shaped skull. Hepatosplenomegaly is common in children, but because of repeated infarctions and subsequent fibrosis (autosplenectomy), the spleen in adults is commonly very small. Cardiomegaly and systolic ejection (flow) murmurs are common. Cholelithiasis and chronic punched-out ulcers around the ankles are common.
Painful crisis causes severe pain in long bones (eg, pretibial pain), the hands and feet (eg, hand-foot syndrome), and joints. Joint pain may result from hemarthrosis or avascular necrosis of the femoral head. Severe abdominal pain may develop with or without vomiting and, when due to sickling itself, is usually accompanied by back and joint pain.
Acute chest syndrome is characterized by sudden onset of fever, chest pain, and pulmonary infiltrates. The infiltrates begin in the lower lobes, are bilateral in 1/3 of cases, and may be accompanied by pleural effusion. It may follow bacterial pneumonia. Hypoxemia may develop rapidly, causing dyspnea.
Patients who are heterozygous (Hb AS) do not experience hemolysis, painful crises, or thrombotic complications except possibly during hypoxic conditions (eg, at high altitudes, during sudden decompression in airplanes). However, rhabdomyolysis and sudden death may occur during sustained, exhausting exercise. Impaired ability to concentrate urine (hyposthenuria) is common. Unilateral hematuria (by unknown mechanisms and usually from the left kidney) can occur but is self-limited. Typical renal papillary necrosis can occur but is less common than among homozygous patients.
The type of testing done depends on the age of the patient. DNA testing can be used for prenatal diagnosis or to confirm a diagnosis of the sickle cell genotype. Screening of neonates is available in most US states and involves Hb electrophoresis. Screening and diagnosis in children and adults involve examination of the peripheral smear, Hb solubility testing, and Hb electrophoresis.
The sensitivity of prenatal diagnosis has been greatly improved with the availability of the PCR technique. It is recommended for families at risk for sickle cell (eg, couples with medical or family histories of anemia or of suggestive ethnic background). DNA samples can be obtained by chorionic villus sampling at 8 to 10 wk gestation. Amniotic fluid can also be tested at 14 to 16 wk. Diagnosis is important for genetic counseling.
Universal testing is currently recommended and is frequently one of a battery of newborn screening tests. To distinguish between Hbs F, S, A, and C, the recommended tests are Hb electrophoresis using cellulose acetate or acid citrate agar, thin-layer isoelectric focusing, or Hb fractionation by high performance liquid chromatography (HPLC). Repeat testing at age 3 to 6 mo may be necessary for confirmation. Solubility testing for Hb S is unreliable during the first few months of life.
Screening and diagnosis of children and adults:
Patients with a family history of sickle cell disease or trait should be screened with peripheral smear, Hb solubility testing, and Hb electrophoresis.
Patients with symptoms or signs suggesting the disorder or its complications (eg, poor growth, acute and unexplained bone pain, aseptic necrosis of the femoral head, unexplained hematuria), and black patients with normocytic anemia (particularly if hemolysis is present) require laboratory tests for hemolytic anemia (see Anemias Caused by Hemolysis: Autoimmune Hemolytic Anemia), Hb electrophoresis, and examination of RBCs for sickling. If sickle cell disease is present, RBC count is usually between 2 and 3 million/μL with Hb reduced proportionately; cells are normocytic (microcytosis suggests a concomitant α-thalassemia). Nucleated RBCs frequently appear in the peripheral blood, and reticulocytosis ≥ 10% is common. Dry-stained smears may show sickled RBCs (crescent-shaped, often with elongated or pointed ends).
The homozygous state is differentiated from other sickle hemoglobinopathies by electrophoresis showing only Hb S with a variable amount of Hb F. The heterozygote is differentiated by the presence of more Hb A than Hb S on electrophoresis. Hb S must be distinguished from other Hb with a similar electrophoretic pattern by showing the pathognomonic RBC morphology.
Bone marrow examination is not used for diagnosis. If it is done to differentiate other anemias, it shows hyperplasia, with normoblasts predominating; bone marrow may become aplastic during sickling or severe infections. ESR, if done to exclude other disorders (eg, juvenile RA causing hand and foot pain), is low. Incidental findings on skeletal x-rays may include widening of the diploic spaces of the skull and a sun-ray appearance of the diploic trabeculations. The long bones often show cortical thinning, irregular densities, and new bone formation within the medullary canal. Unexplained hematuria, even among patients not suspected of having sickle cell disease, should prompt consideration of sickle cell trait.
Evaluation of exacerbations:
If patients with known sickle cell disease have acute exacerbations, including pain, fever, or other symptoms of infection, aplastic crisis is considered and CBC and reticulocyte count are done. Reticulocyte count < 1% suggests aplastic crisis, particularly when Hb decreases below the patient's usual level. In a painful crisis without aplasia, WBC count rises, often with a shift to the left, particularly during bacterial infection. Platelet count usually increases. If measured, serum bilirubin is usually elevated (eg, 2 to 4 mg/dL [34 to 68 μmol/L]), and urine may contain urobilinogen.
In patients with chest pain or difficulty breathing, acute chest syndrome and pulmonary embolism are considered; chest x-ray and pulse oximetry are necessary. Hypoxemia or pulmonary parenchymal infiltrates on chest x-ray suggest acute chest syndrome or pneumonia. Hypoxemia without pulmonary infiltrates suggests pulmonary embolism.
In patients with fever, infection and acute chest syndrome are considered; cultures, chest x-ray, and other appropriate diagnostic tests are done.
The life span of homozygous patients has steadily increased to > 50 yr. Common causes of death are acute chest syndrome, intercurrent infections, pulmonary emboli, infarction of a vital organ, and renal failure.
Treatment includes regular health maintenance measures as well as specific treatment of the complications as they arise. Complications are treated supportively. No effective in vivo anti-sickling drug is available. Splenectomy is valueless. Stem cell transplantation has been curative in a small number of patients but has a 5 to 10% mortality rate and so is not commonly done. Gene therapy offers hope for a cure, but it is still under study.
Indications for hospitalization include suspected serious (including systemic) infection, aplastic crisis, acute chest syndrome, and, often, intractable pain or the need for transfusion. Fever alone may not be a reason to hospitalize. However, patients who appear acutely ill and have a temperature > 38° C should be admitted so that cultures can be obtained from multiple areas and IV antibiotics can be given.
Patients with suspected serious bacterial infections or acute chest syndrome require broad-spectrum antibiotics immediately.
Painful crises are managed with liberal administration of analgesics, usually opioids. IV morphine (continuous or bolus) is effective and safe; meperidine is avoided. Although dehydration contributes to sickling and may precipitate crises, it is unclear whether vigorous hydration is helpful during crises. Nevertheless, maintaining normal intravascular volume has been a mainstay of therapy. During crises, pain and fever may persist for as long as 5 days.
Transfusion is given in many situations in which its efficacy has not been demonstrated. However, routine transfusion therapy is indicated for prevention of recurrent cerebral thrombosis, especially in children. Transfusion is usually done when Hb is < 5 g/dL. Specific indications include acute splenic sequestration, aplastic crises, cardiopulmonary symptoms or signs (eg, high-output heart failure, hypoxemia with PO2
< 65 mm Hg), preoperative use, priapism, and life-threatening events that would benefit from improved O2 delivery (eg, sepsis, severe infection, acute chest syndrome, stroke, acute organ ischemia). Transfusion is not helpful during an uncomplicated painful crisis; however, it may break a cycle of closely spaced painful crises. Transfusion may be needed in pregnancy.
Partial exchange transfusion is usually preferred to simple transfusion if routine or multiple transfusions are necessary. It can be done with modern apheresis machines. If the initial Hb is low (< 7 g/dL), this process cannot be initiated before first transfusing red cells. Partial exchange transfusion minimizes iron accumulation and hyperviscosity.
For long-term management the following interventions have reduced mortality, particularly during childhood:
Supplemental folate, 1 mg po once/day, is usually prescribed.
Hydroxyurea, by increasing Hb F and thereby reducing sickling, decreases painful crises (by 50%) and decreases acute chest syndrome and transfusion requirements. The dose of hydroxyurea is variable and is adjusted to increase Hb F. Hydroxyurea may be more effective when combined with erythropoietin (eg, 40,000 to 60,000 units/wk). However, hydroxyurea is a leukemogen and causes neutropenia and thrombocytopenia. It is also a teratogen and should not be given to females of child-bearing age.
Erythropoietin use in patients with anemia unrelated to chemotherapy has been associated with increased frequency of venous thromboembolic events and cardiopulmonary complications (eg, MI); it is generally not helpful in patients with sickle cell disease.
Last full review/revision February 2009 by Alan E. Lichtin, MD
Content last modified February 2012